Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Botulinum Toxin A Ameliorates Neuroinflammation in the MPTP and 6-OHDA-Induced Parkinson's Disease Models

  • Ham, Hyeon Joo (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Yeo, In Jun (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Jeon, Seong Hee (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Lim, Jun Hyung (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Yoo, Sung Sik (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Son, Dong Ju (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Jang, Sung-Su (ATGC Co.) ;
  • Lee, Haksup (ATGC Co.) ;
  • Shin, Seung-Jin (ATGC Co.) ;
  • Han, Sang Bae (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Yun, Jae Suk (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Hong, Jin Tae (College of Pharmacy and Medical Research Center, Chungbuk National University)
  • Received : 2021.04.20
  • Accepted : 2021.05.17
  • Published : 2022.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Recently, increasing evidence suggests that neuroinflammation may be a critical factor in the development of Parkinson's disease (PD) in addition to the ratio of acetylcholine/dopamine because dopaminergic neurons are particularly vulnerable to inflammatory attack. In this study, we investigated whether botulinum neurotoxin A (BoNT-A) was effective for the treatment of PD through its anti-neuroinflammatory effects and the modulation of acetylcholine and dopamine release. We found that BoNT-A ameliorated MPTP and 6-OHDA-induced PD progression, reduced acetylcholine release, levels of IL-1β, IL-6 and TNF-α as well as GFAP expression, but enhanced dopamine release and tyrosine hydroxylase expression. These results indicated that BoNT-A had beneficial effects on MPTP or 6-OHDA-induced PD-like behavior impairments via its anti-neuroinflammation properties, recovering dopamine, and reducing acetylcholine release.

Keywords

Acknowledgement

This work is financially supported by the National Research Foundation of Korea [NRF] Grant funded by the Korea government (MSIP) (No. MRC, 2017R1A5A2015541).

References

  1. Antipova, V., Hawlitschka, A., Mix, E., Schmitt, O., Drager, D., Benecke, R. and Wree, A. (2013) Behavioral and structural effects of unilateral intrastriatal injections of botulinum neurotoxin a in the rat model of Parkinson's disease. J. Neurosci. Res. 91, 838-847. https://doi.org/10.1002/jnr.23210
  2. Boll, M. C., Alcaraz-Zubeldia, M. and Rios, C. (2011) Medical management of Parkinson's disease: focus on neuroprotection. Curr. Neuropharmacol. 9, 350-359. https://doi.org/10.2174/157015911795596577
  3. Bonte, M.-A., El Idrissi, F., Gressier, B., Devos, D. and Belarbi, K. (2021) Protein network exploration prioritizes targets for modulating neuroinflammation in Parkinson's disease. Int. Immunopharmacol. 95, 107526. https://doi.org/10.1016/j.intimp.2021.107526
  4. Butler, C. A., Popescu, A., Kitchener, E., Allendorf, D. H., Puigdellivol, M. and Brown, G. C. (2021) Microglial phagocytosis of neurons in neurodegeneration, and its regulation. J. Neurochem. doi: 10.1111/jnc.15327 [Online ahead of print].
  5. Chaudhuri, K. R., Healy, D. G. and Schapira, A. H. (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 5, 235-245. https://doi.org/10.1016/S1474-4422(06)70373-8
  6. Choi, D. Y., Lee, M. K. and Hong, J. T. (2013) Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration. Neurobiol. Dis. 49, 159-168. https://doi.org/10.1016/j.nbd.2012.08.001
  7. Coffield, J. A. and Yan, X. (2009) Neuritogenic actions of botulinum neurotoxin A on cultured motor neurons. J. Pharmacol. Exp. Ther. 330, 352-358. https://doi.org/10.1124/jpet.108.147744
  8. Connolly, B. S. and Lang, A. E. (2014) Pharmacological treatment of Parkinson disease: a review. JAMA 311, 1670-1683. https://doi.org/10.1001/jama.2014.3654
  9. Day, M., Wang, Z., Ding, J., An, X., Ingham, C. A., Shering, A. F., Wokosin, D., Ilijic, E., Sun, Z. and Sampson, A. R. (2006) Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat. Neurosci. 9, 251-259. https://doi.org/10.1038/nn1632
  10. Ding, J., Guzman, J. N., Tkatch, T., Chen, S., Goldberg, J. A., Ebert, P. J., Levitt, P., Wilson, C. J., Hamm, H. E. and Surmeier, D. J. (2006) RGS4-dependent attenuation of M 4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. Nat. Neurosci. 9, 832-842. https://doi.org/10.1038/nn1700
  11. Hawlitschka, A., Antipova, V., Schmitt, O., Witt, M., Benecke, R., Mix, E. and Wree, A. (2013) Intracerebrally applied botulinum neurotoxin in experimental neuroscience. Curr. Pharm. Biotechnol. 14, 124-130. https://doi.org/10.2174/138920113804805331
  12. Hwang, C. J., Kim, Y. E., Son, D. J., Park, M. H., Choi, D. Y., Park, P. H., Hellstrom, M., Han, S. B., Oh, K. W., Park, E. K. and Hong, J. T. (2017) Parkin deficiency exacerbate ethanol-induced dopaminergic neurodegeneration by P38 pathway dependent inhibition of autophagy and mitochondrial function. Redox. Biol. 11, 456-468. https://doi.org/10.1016/j.redox.2016.12.008
  13. Jankovic, J. (2004) Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatry 75, 951-957. https://doi.org/10.1136/jnnp.2003.034702
  14. Knuepfer, S. and Juenemann, K. P. (2014) Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice. Ther. Adv. Urol. 6, 34-42. https://doi.org/10.1177/1756287213510962
  15. Liu, M. and Bing, G. (2011) Lipopolysaccharide animal models for Parkinson's disease. Parkinsons Dis. 2011, 327089.
  16. Marsden, C. (1982) The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology 32, 514-539. https://doi.org/10.1212/WNL.32.5.514
  17. Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M. and Nagatsu, T. (1994) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180, 147-150. https://doi.org/10.1016/0304-3940(94)90508-8
  18. Munoz-Lora, V. R. M., Abdalla, H. B., Cury, A. A. D. B. and Clemente-Napimoga, J. T. (2020) Modulatory effect of botulinum toxin type A on the microglial P2X7/CatS/FKN activated-pathway in antigeninduced arthritis of the temporomandibular joint of rats. Toxicon 187, 116-121. https://doi.org/10.1016/j.toxicon.2020.08.027
  19. Oldenburg, I. A. and Ding, J. B. (2011) Cholinergic modulation of synaptic integration and dendritic excitability in the striatum. Curr. Opin. Neurobiol. 21, 425-432. https://doi.org/10.1016/j.conb.2011.04.004
  20. Paxinos, G. and Watson, C. (2006) The Rat Brain in Stereotaxic Coordinates. Hard cover ed. Elsevier.
  21. Piotrowska, A., Popiolek-Barczyk, K., Pavone, F. and Mika, J. (2017) Comparison of the expression changes after botulinum toxin type A and minocycline administration in lipopolysaccharide-stimulated rat microglial and astroglial cultures. Front. Cell. Infect. Microbiol. 7, 141. https://doi.org/10.3389/fcimb.2017.00141
  22. Pott Godoy, M. C., Tarelli, R., Ferrari, C. C., Sarchi, M. I. and Pitossi, F. J. (2008) Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 131, 1880-1894. https://doi.org/10.1093/brain/awn101
  23. Pringsheim, T., Jette, N., Frolkis, A. and Steeves, T. D. (2014) The prevalence of Parkinson's disease: a systematic review and metaanalysis. Mov. Disord. 29, 1583-1590. https://doi.org/10.1002/mds.25945
  24. Rojewska, E., Piotrowska, A., Popiolek-Barczyk, K. and Mika, J. (2018) Botulinum toxin type A-a modulator of spinal neuron-glia interactions under neuropathic pain conditions. Toxins 10, 145. https://doi.org/10.3390/toxins10040145
  25. Rossetto, O., Megighian, A., Scorzeto, M. and Montecucco, C. (2013) Botulinum neurotoxins. Toxicon 67, 31-36. https://doi.org/10.1016/j.toxicon.2013.01.017
  26. Sahinkanat, T., Ozkan, K. U., Ciralik, H., Ozturk, S. and Resim, S. (2009) Botulinum toxin-A to improve urethral wound healing: an experimental study in a rat model. Urology 73, 405-409. https://doi.org/10.1016/j.urology.2008.07.051
  27. Stubblefield, M. D., Levine, A., Custodio, C. M. and Fitzpatrick, T. (2008) The role of botulinum toxin type A in the radiation fibrosis syndrome: a preliminary report. Arch. Phys. Med. Rehabil. 89, 417-421. https://doi.org/10.1016/j.apmr.2007.11.022
  28. Wang, L., Wang, K., Chu, X., Li, T., Shen, N., Fan, C., Niu, Z., Zhang, X. and Hu, L. (2017) Intra-articular injection of Botulinum toxin A reduces neurogenic inflammation in CFA-induced arthritic rat model. Toxicon 126, 70-78. https://doi.org/10.1016/j.toxicon.2016.11.009
  29. Wree, A., Mix, E., Hawlitschka, A., Antipova, V., Witt, M., Schmitt, O. and Benecke, R. (2011) Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson's disease. Neurobiol. Dis. 41, 291-298. https://doi.org/10.1016/j.nbd.2010.09.017
  30. Zhang, L. Y., Jin, Q. Q., Holscher, C. and Li, L. (2021a) Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model. Neural Regen. Res. 16, 1660-1670. https://doi.org/10.4103/1673-5374.303045
  31. Zhang, Z., Hao, L., Shi, M., Yu, Z., Shao, S., Yuan, Y., Zhang, Z. and Holscher, C. (2021b) Neuroprotective effects of a GLP-2 analogue in the MPTP Parkinson's disease mouse model. J. Parkinsons Dis. 11, 529-543. https://doi.org/10.3233/JPD-202318
  32. Zhao, Y. F., Tang, Y. and Illes, P. (2021) Astrocytic and oligodendrocytic P2X7 receptors determine neuronal functions in the CNS. Front. Mol. Neurosci. 14, 641570. https://doi.org/10.3389/fnmol.2021.641570